Submission of Newspaper Advertisement of Unaudited Financial Results for the First Quarter Ended June 30, 2025 of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemo Pharma Laboratories Ltd (note: filing source lists Star Source Multi Trade Ltd) has submitted copies of newspaper advertisements of its unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025) to BSE, as published in Business Standard and Mumbai Lakshdeep on August 14, 2025. The results show a dramatic deterioration: Total Income from Operations fell to Rs. 207.12 thousand from Rs. 3,018 thousand in the same quarter last year, and the company swung from a profit after tax of Rs. 2,466 thousand in Q1 FY25 to a massive loss after tax of Rs. 1,18,050.65 thousand in Q1 FY26. Net loss before tax is also Rs. 1,18,050.65 thousand versus a profit of Rs. 2,466 thousand a year ago, and Basic/Diluted EPS turned deeply negative at Rs. (78.70) versus Rs. 1.64 earlier. Equity share capital stood at Rs. 15,000 thousand and reserves turned negative at Rs. (1,604.41) thousand, raising concerns about balance sheet stress. The results were reviewed by the Audit Committee and approved by the Board on August 12, 2025.
Highly negative for shareholders - the company has reported a staggering quarterly loss and sharp revenue decline compared to the year-ago quarter, alongside negative reserves. The stock is likely to face significant selling pressure; investors should note the very small scale of operations and weak financial position.